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Introduction: Portal hypertension (PH) is characterized by vasodilatation in the portal system
and the bowel is one of the severely affected organs. N-acetylcysteine (NAC) is a molecule
with important properties and widely used in clinical practice.
Objective: To evaluate NAC action in the bowel of animals submitted to the animal model of
partial portal vein ligation (PPVL).
Methods: 18 male Wistar rats were divided into three experimental groups (n = 6): sham-
operated (SO), PPVL, and PPVL + NAC. On the 8th day after surgery, N-acetylcysteine
(10  mg/kg, ip) was administered daily for 7 days. On the 15th day the animals’ bowel was
collected for oxidative stress analysis, immunohistochemistry and Western blot. We evalu-
ated  the expression of NF-KB and TNF- by immunohistochemistry and of iNOS by Western
blot. Lipid peroxidation was assessed by TBARS technique, and the activities of antioxidant
enzymes superoxide dismutase (SOD) and glutation peroxidase (GPx) were checked.
Results: We  observed an increased expression of NF-KB and TNF- in PPVL group, and an
increased iNOS expression assessed by Western blot. NAC reduced the expression of all
proteins evaluated. We  also observed an increase in oxidative stress in the bowel of mice
PPVL group compared to controls (SO), and NAC was effective in reducing these values in
PPVL  + NAC group. Also, a reduction in the activity of SOD and GPx enzymes was observed
in  the diseased group, and NAC was able to restore the activity of the enzymes assessed.
Conclusion: We  suggest the anti-inﬂammatory and antioxidant action of NAC in the bowel
of  animals submitted to PPVL model.
©  2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This
is  an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
∗ Corresponding author.
E-mail: francielli.licks@gmail.com.br (F. Licks).
ttp://dx.doi.org/10.1016/j.jcol.2016.05.005
237-9363/© 2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Alterac¸ões  intestinais  inﬂamatórias  e  de  estresse  oxidativo  em  modelo
experimental  de  hipertensão  portal:  ac¸ão  da  N-acetilcisteína
Palavras-chave:
N-Acetilcisteína
Hipertensão Portal
Intestino
Estresse Oxidativo
Inﬂamac¸ão
r  e  s  u  m  o
Introduc¸ão: A Hipertensão Portal (HP) é caracterizada por uma vasodilatac¸ão no sistema
portal, e o intestino é um dos órgãos gravemente acometidos. A N-acetilcisteína (NAC) é
uma molécula com importantes propriedades, amplamente utilizada na clínica.
Objetivo: Avaliar a ac¸ão da NAC no intestino de animais submetidos ao modelo animal de
ligadura parcial da veia porta (LPVP).
Métodos: Foram utilizados 18 ratos machos Wistar divididos em três grupos experimentais
(n  = 6): Sham-operated (SO), LPVP, LPVP + NAC. No 8◦ dia após a cirurgia, a N-acetilcisteína
(10  mg/kg,ip) foi administrada diariamente durante 7 dias. No 15◦ dia foi coletado o intestino
dos  animais para análises de estresse oxidativo, imunohistoquímica e Western blot. Nós
avaliamos a expressão do NF-kb e TNF- por imunohistoquímica e da iNOS por Western
blot.  A lipoperoxidac¸ão foi avaliada pela técnica de TBARS, e as atividades das enzimas
antioxidantes Superóxido Dismutase (SOD) e GlutationaPeroxidase (GPx) foram veriﬁcadas.
Resultados: Observamos um aumento da expressão do NF-kb e TNF- no grupo LPVP, e
aumento na expressão da iNOS avaliada por Western blot. A NAC reduziu a expressão de
todas  as proteínas avaliadas. Observamos um aumento do estresse oxidativo no intestino
dos  ratos do grupo LPVP com relac¸ão aos controles (SO), sendo a NAC eﬁcaz na reduc¸ão
desses valores no grupo LPVP + NAC. Ainda, uma reduc¸ão na atividade das enzimas SOD e
GPx no grupo doente, sendo a NAC capaz de restaurar a atividade das enzimas avaliadas.
Conclusão: Sugerimos a ac¸ão anti-inﬂamatória e antioxidante da NAC no intestino de ani-
mais submetidos ao modelo LPVP.
©  2016 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. Este
e´  um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://creativecommons.org/Introduction
Portal hypertension (PH) is a syndrome whose clinical picture
is established by the emergence of an anatomical obstacle in
the portal system. This obstacle, which blocks the blood ﬂow,
causes blood damming at the site of obstruction. The compen-
satory mechanism of decompression in the portal system is
the development of an important vasodilation in the splanch-
nic territory; in turn, this event is responsible for the main
complications of the portal hypertension syndrome.1
We  can correlate the development of a hyperdynamic col-
lateral circulation with one of the major complications from
PH: the bleeding from gastrointestinal varices, an event that
is triggered when the portal pressure gradient rises above
12 mmHg.2 The progressive vasodilation in the splanchnic ter-
ritory is responsible for the appearance of these varicose veins,
the most important being those located in the stomach and
bowel. These conditions are known as Portal Hypertension
Gastropathy (PHG) and Portal Hypertensive Colopathy (PHC),
respectively, and the ﬁrst of these conditions is already well
established in the literature.3
Intestinal changes present in PH are still being elucidated
and were gradually identiﬁed over the last decade as being
mainly one of the causes of fatal gastrointestinal bleeding in
4patients with PH. The pattern of lesions in cases of PH can
be found in other parts of the gastrointestinal tract, including
the intestine,5 due to mucosal edema, inﬂammatory diseases,
and ectopic and anorectal varices.6licenses/by-nc-nd/4.0/).
The experimental model of Partial Portal Vein Ligation
(PPVL) has been used by many  authors to study the molecu-
lar changes in pre-hepatic portal hypertension.7–9 In rats, the
hemodynamic changes present in PH show up around the day
14 after surgery, and hyperdynamic circulation and splanch-
nic vasodilation are prevailing conditions in animals subjected
to a PPVL model.10 In addition, PHC and encephalopathy are
among the most important manifestations resulting from
this experimental model, and inﬂammatory mechanisms are
aggravating factors in both manifestations.11
Inﬂammation is an event often associated with injuries of
different origins. In the case of PH, systemic and splanch-
nic vascular responses appear to play an important role in
the pathogenesis of hyperdynamic circulation and are very
similar to those produced in the post-traumatic inﬂamma-
tory response. The mechanical stress caused by the increased
blood ﬂow in the splanchnic territory stimulates the endothe-
lium to secrete vasoactive substances, cytokines and growth
factors, and this is a triggering factor for local or generalized
inﬂammation.12
With respect to local inﬂammation, it is important to
mention that the mucosa of the gastrointestinal tract is a
major reservoir of macrophages and mast cells, and these
cells located in the intestine are considered as effector cells
that participate in the ﬁrst line of defense of our body.13In the case of inﬂammation, the intestinal mucosa acquires
a phenotypic pro-inﬂammatory proﬁle, secreting cytokines
that can amplify the systemic inﬂammatory vascular
response.12
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for subsequent analysis. A portion of the collected materialj coloproctol (rio j). 
Among the cytokines secreted by the intestine after the ini-
ial stimulation, one must mention the tumor necrosis factor
TNF-), released by mast cells of the intestine and mesen-
eric lymph nodes. This proinﬂammatory cytokine is probably
elated not only to the inﬂammatory process present in PH but
lso to the development of hyperdynamic circulation, since it
timulates the primary route of splanchnic vasodilation, nitric
xide.14 In addition, TNF- is an extracellular stimulus for
elease of another pro-inﬂammatory cytokine, NF-kB. This fac-
or induces phosphorylation in IkB, the cytoplasmic inhibitory
rotein that prevents the nuclear translocation of NF-kB.15
The activation of nitric oxide (NO) is the main event
roposed as a triggering factor for the development of col-
ateral circulation in cases of PH. NO is synthesized by nitric
xide synthase (NOS), including, among its major isoforms,
ndothelial nitric oxide synthase (eNOS), neuronal nitric oxide
ynthase (nNOS), and inducible nitric oxide synthase (iNOS).
his latter isoform is associated with increased levels of
O production.16iNOS is mainly expressed in macrophages
nd smooth muscle cells, especially after the stimulation
y lipopolysaccharides, or inﬂammatory cytokines.17 This
nzyme is modulated by transcription factors, among which
F-kB is considered the primary mediator of its activation,
hich, in turn, can be activated by the oxidative stress.18
Inﬂammatory cells are important sources for the gen-
ration of reactive oxygen species; thus the oxidative and
nﬂammatory damage acts synergistically in the develop-
ent and worsening of conditions in which these events are
resent.19
With HP, the role of oxidative stress is associated with
he overproduction of nitric oxide, which determines the
roduction of highly reactive species, for example, peroxy-
itrite (ONOO ).20 Using the PPVL model, previous studies
ublished by our study group have already shown this signif-
cant involvement in the pathogenesis of pre-hepatic portal
ypertension9,21,22 as well as the participation of inﬂamma-
ion in gastric injury in this experimental model.23
This study aimed to evaluate the involvement of oxida-
ive and inﬂammatory stress in the intestinal mucosa of rats
ith pre-hepatic portal hypertension. In addition, we aimed
o evaluate the antioxidant and anti-inﬂammatory action of
-acetylcysteine in intestinal injuries present in PPVL model.
aterial  and  methods
thics
he experimental procedures with animals were carried out
n accordance with the current Brazilian legislation in the
ractice of scientiﬁc research (Law 11,794, Ofﬁcial Gazette –
ctober 8, 2008), Euthanasia Practice Guidelines of CONCEA
2013) and Brazilian Guidelines for the Care and Use of Animals
or Scientiﬁc and Didactic Purposes – DBCA (2013).
nimalshe animals were acquired in the vivarium of HCPA according
o the speciﬁcations of the Animal Experimentation Unit (UEA)
nd were maintained throughout the experiment in plastic;3 6(4):231–239 233
cages measuring 47 cm × 34 cm × 18 cm,  lined with wood shav-
ings, in a 12-h light/dark cycle and at a temperature of
22 ± 4 ◦C. All animals were fed a commercially available ani-
mal food (Purina® – Nutripal, Porto Alegre, RS, Brazil) and had
access to water ad libitum.
Groups  and  experimental  protocols
For this study, we used 18 male Wistar rats (±250 g) which were
divided randomly into three groups (n = 6): sham-operated
(SO), PPVL, and PPVL + NAC.
On the ﬁrst day of the experiment, the animals were
weighed and anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg) intraperitoneally (IP). We  performed local
asepsis and then made a mid-ventral laparotomy with a care-
ful exposure of bowel loops with a gauze pad soaked in
saline. All animals underwent the same surgical procedure;
however, the animals in group SO were submitted only to
the manipulation of the portal vein. The animals of PPVL
and PPVL + NAC groups were submitted to an experimental
model of Partial Portal Vein Ligature, described by Sikuler et al.
1985.7
We  used a 20G needle to promote a partial obstruction of
the portal vein; for this purpose, both the vessel and the nee-
dle were tied with silk 3-0. The immediate vasodilation of
the splanchnic territory was observed and then the needle
was gently withdrawn, leaving only the portal vein partially
occluded. Next, intestinal loops were replaced into the abdom-
inal cavity of the animals, and an infusion of 10 mL  of saline
was administered, and the peritoneum was sutured with con-
tinuous points. The epithelial layer was closed with individual
sutures. The above-described model features a pre-hepatic
portal hypertension.7
After completion of the surgical procedures, the animals
were placed in individual cages for their recovery under anal-
gesia with dipyrone (200 mg/kg); the ﬁrst administration was
performed by intramuscular route and the remaining was
orally administered with a frequency of 8/8 h during the sub-
sequent 72 h.
Seven days after surgery, the treatment was initiated in
the respective groups. The animals in OS and PPVL groups
received only the vehicle (0.9% NaCl, 0.6 mL  IP). On the
other hand, the animals in PPVL + NAC group received N-
acetylcysteine (Sigma Chemical Co., St. Louis, MO, USA; CAS
registry number 616-91-1) at a dose of 10 mg/kg dissolved in
0.6 mL  of 0.9% NaCl. The treatment was carried out beginning
on the 8th day, for seven days.
Euthanasia  and  tissue  collection
At the end of treatment on day 15, the animals were again
weighed and anesthetized using the same protocol described
above. After an inspection of the animal’s state of anesthe-
sia, a new laparotomy was made for removal of the intestineswas stored in a freezer at −80 ◦C, and the remainder was ﬁxed
in 10% buffered formalin for 24 h. After this period, 3-mm
sections of the parafﬁn block were obtained using a rotary
microtome.
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Immunohistochemistry
The histological technique of immunohistochemistry was
used to evaluate the expression of the nuclear factor kappa
B (NF-kB) and tumor necrosis factor (TNF-)  in the animal’s
intestine. The reacquisition of the antigen was carried out
using a buffer at 100 ◦C; subsequently, the activity of endoge-
nous peroxidase was blocked by incubation with absolute
methanol. The slides were incubated with rabbit polyclonal
antibody (NF- [sc-9072], 1: 200, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and goat monoclonal antibody (TNF-
[sc-1351], 1: 200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4 ◦C. Next, the material was washed and
incubated with the secondary antibody goat anti-rabbit IgG-
HRP (sc-2004) for 30 min  at room temperature. The slides were
analyzed using a microscope equipped with a digital camera,
and the images were captured using the Image-Plus software
(Media Cybernetics, Bethesda, MD, USA). Quantiﬁcation of the
marking of both analytes was carried out by digital analysis
with Adobe Photoshop® CS3 extended 10.0, using the count-
ing of brown color stained pixels. The expression level was
determined by multiplying the average density of the image
by the percentage of the stained areas.24
Western  blot
The cytosolic extracts prepared on the basis of intestinal
homogenates were used in Western blot, and protein values
were determined by the Bradford method.25 Then, protein
lysates were fractionated by polyacrylamide gel electrophore-
sis at 9–12% in an electrophoresis buffer (25 mM Tris, 0.2 M
glycine, 3.5 mM SDS, pH 8.8) and then transferred to mem-
branes of polyvinylidene ﬂuoride (PVDF). Blocking of the
membranes was done using a 5% solution of skimmed
milk powder in PBS-Tween. Then, the PVDF membrane
was incubated overnight at 4 ◦C with the speciﬁc mono-
clonal primary antibody, mouse polyclonal antibody (NOS2
[sc-7271], Santa Cruz Biotechnology, Santa Cruz, CA, USA).
After the overnight incubation, the membranes were washed
with TTBS and incubated for 1 h at room temperature with
the secondary antibody IgG-HRP sc-2005, anti-goat donkey
(sc-2020, Santa Cruz Biotechnology, Santa Cruz, CA, USA,
1:4000). After revealed, the bands were quantiﬁed using the
Scion Image  program, v. 4.02 for Windows (Scion Corpora-
tion, Frederick, USA). The results were expressed in arbitrary
units.26
Biochemical  analyses
Homogenate
The intestines of the animals were homogenized for 1 min
with Ultra-Turrax (IKA-WERK) in the presence of potassium
chloride (KCl) 1.15% (5 mL/g of tissue) and phenylmethyl-
sulfonyl ﬂuoride (PMSF) at a concentration of 100 mM in
isopropanol (10 L/mL KCl added). Then, the homogenates
were centrifuged for 10 min  at 3000 rpm (1110 × g) in a refrig-
erated centrifuge (SORVALL RC-5B Refrigerated Superspeed
Centrifuge) and the supernatant was removed and frozen in a
freezer at −80 ◦C for subsequent measurements.27 1 6;3  6(4):231–239
Protein  content
The protein concentration in the homogenates was deter-
mined by the Bradford method, with bovine albumin (SIGMA)
used as a standard. The samples were measured spectropho-
tometrically at 595 nm,  and the values were expressed in
mg/mL. These values were used to calculate subsequently
TBA-RS and the values of antioxidant enzymes SOD and
GPx.25
Determination  of  oxidative  stress
For the determination of lipid peroxidation, we used the
method of reactive substances to thiobarbituric acid (TBA-
RS). The technique consists in heating the homogenate in the
presence of thiobarbituric acid, with consequent formation
of a pink color product, measured in a spectrophotometer at
535 mm.  The appearance of color occurs due to the presence
of malondialdehyde and other substances from lipid peroxida-
tion in biological material. 0.5 mL  of thiobarbituric acid (TBA)
0.67%, 0.25 mL  of distilled water, 0.75 mL  of trichloroacetic
acid (TCA) 10%, and 0.25 mL of the homogenate were placed
in a test tube, in this order. TBA reacts with lipid peroxi-
dation products forming a Schiff base, and TCA exerts the
function of denaturation of the proteins present and also
acidiﬁes the reaction medium. Then, each tube was stirred
and heated to 100 ◦C for 15 min. After that, the tubes were
cooled and 1.5 mL  of n-butyl alcohol was added to extract
the pigment formed. The tubes were placed on a shaker
(Biomatic) for 45 s and centrifuged for 10 min  at 3000 rpm
(1110 × g). Finally, the stained product was taken away and
the reading was taken using a spectrophotometer (CARY 3E
– UV – Visible Varian Spectrophotometer) at a wavelength of
535 nm.  The concentration of TBA-RS is expressed as nmol/mg
protein.28
The activity of superoxide dismutase (SOD) is deﬁned by its
ability to inhibit a detection system which reacts with O2•−.
For this purpose, adrenaline is used, which, in an alkaline
medium, turns to adrenochrome, producing O2•−, which it is
the substrate of the enzyme. Before performing the determi-
nation with the homogenate, measurement of the reaction
medium (50 mM glycine-NaOH, pH 9.6) was carried out with
50 L of adrenaline (60 mM,  pH 2.0), corresponding to 100% of
the reaction. This mixture was stirred and read at 480 nm.
Subsequently, different volumes of the homogenate (50 L,
25 L, and 10 L) were added, and the inhibition of the reac-
tion was measured. The enzymatic activity was expressed as
SOD units/g of tissue (quantity of SOD able to inhibit in 50%
the adrenaline reduction rate).29
The determination of glutathione peroxidase (GPx) using
the Flohé–Guntzler method30 consists in measuring the
NADPH consumption rate in a system containing GSH; the oxi-
dation is recorded spectrophotometrically at a wavelength of
340 nm.  To this end, 2.7 mL  of a regulating solution of Na+ and
K+ phosphates (100 mM,  pH 7.0) with 50 L of NADPH (10 mM),
150 L of BOOH (10 mM)  and 50 L of glutathione reductase
(12 U/mL) were placed in a quartz cuvette. The mixture was
read for 1 min; at this point, a baseline was established, and
then 50 L of GSH (100 mM)  and 50 L of the homogenate were
added. The samples were incubated at 25 ◦C for 5 min  and read
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Fig. 1 – Immunohistochemistry of TNF-. Effects of partial portal vein ligation (PPVL) and N-acetylcysteine (NAC)
administration on TNF- expression. SO, Sham-operated group; PPVL, partial portal vein ligation; PPVL + NAC, partial portal
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t an absorbance of 340 nm.  The activity was expressed in
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tatistical  analysis
ll data were presented as a mean ± standard error. Statistical
nalyses were calculated using Graphpad Instat software, ver-
ion 3.0 for Windows. Analysis of variance (ANOVA) and the
tudent–Newman–Keuls test was used for multiple analyses,
nd the signiﬁcance level was set at p < 0.05 (5%).
esults
mmunohistochemistry
n assessing the expression of the protein TNF- in the differ-
nt experimental groups, we observed a signiﬁcant increase in
ts markings in PPVL versus SO group (p < 0.001). The adminis-
ration of N-acetylcysteine in the proposed dose in this study
as able to reduce the expression of TNF- in PPVL + NAC
roup (p < 0.001) (Fig. 1).
The expression of NF-kB was increased in animals
ubjected to the experimental model of PPVL versus con-
rols (p < 0.001), and the values of PPVL + NAC group weresigniﬁcantly reduced versus values for animals of the diseased
group (p < 0.001) (Fig. 2).
Western  blot
Using Western blot, we observed a signiﬁcant increase in
iNOS expression in the intestine of animals of the diseased
group (p < 0.01). The animals treated with NAC had their values
reduced, as observed in PPVL + NAC group (p < 0.01) (Fig. 3).
Biochemical  analyses
An increase was observed in lipid peroxidation, evaluated by
TBA-RS in animals from PPVL versus OS group (p < 0.05), and
NAC was able to reduce these levels when administered to
PPVL + NAC group (p < 0.01) (Fig. 4).
SOD activity was also evaluated in the intestine of animals
of different experimental groups; the activity was reduced in
diseased versus control animals (p < 0.01), and the treatment
has proven effective in increasing the activity of this enzyme
(p < 0.05) (Fig. 5).Another antioxidant enzyme, GPx, was also evaluated
in this study; We  observed a similar behavior in PPVL
(p < 0.05), and in PPVL + NAC groups versus OS group (p < 0.01)
(Fig. 6).
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Discussion
The portal hypertension syndrome shows as characteristics
the occurrence of ascites, hepatic encephalopathy, and a
hyperdynamic collateral circulation31; this latter occurrence
is considered the main cause of worsening of the general con-
dition.
The collateral circulation develops in order to divert the
blood ﬂow from the obstructed territory; and the obstruc-
tion may be situated before (pre-hepatic), into (hepatic) or
after (post-hepatic) the liver.32 Regardless of the place of this
obstruction, the unblocking compensatory mechanism will
eventually result in the formation of varicose veins distributed
along the digestive tract of the patient.
In general, varicose veins located in the colon are prevalent
in the cecum and rectosigmoid region33 and characterize por-
tal hypertension colopathy (PHC). In this scenario, the risk of
bleeding through colonic varices is 1–8%34; on the other hand,
for rectal varicose veins, the risk is from 44 to 89% in cirrhotic
patients.6 In addition, vascular ectasia and microcirculatory
changes along the intestinal mucosa damage its integrity and
promote the development of a local inﬂammatory process.35
The intestinal inﬂammatory condition present in cases of
portal hypertension is considered an aggravating factor in the
pathogenesis of the disease. Among the pro-inﬂammatory
cytokines involved in the process, TNF- is considered as
an important mediator, being produced by intestinal mast
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Fig. 2 – Immunohistochemistry of NF-kB. Effects of partial portal
administration on NF-kB. SO, Sham-operated group; PPVL, partia
ligation treated with NAC. *p < 0.001, #p < 0.001 (n = 6). 1 6;3  6(4):231–239
cells.36 In this study, we observed a signiﬁcant increase of
this cytokine in the intestine of animals of PPVL group (Fig. 1).
The same behavior was observed in the evaluation of NF-kB,
which was increased in relation to the animals of SO group
(Fig. 2). These data are consistent with studies published, that
report leukocyte inﬁltration and an inﬂammatory process in
this same experimental model.37
N-acetylcysteine was able to reduce the expression of both
cytokines evaluated in the intestine of animals of PPVL + NAC
group. The anti-inﬂammatory properties of NAC have been
previously described in inﬂammatory bowel diseases with
encouraging results,38 and these results may be related to its
thiol group, which is important to combat oxidative stress
and inﬂammation.39 In addition, the treatment with NAC
suppresses the activation of NF-kB and the subsequent pro-
duction of its cytokines and also blocks TNF- activation,
causing structural changes in its receptor.40
The involvement of nitric oxide in this experimental model
is well established in the literature. With the progression of
the disease, the immune system is activated and the inducible
form of NOS (iNOS) undergoes up-regulation.40 In this study,
the animals of PPVL group demonstrated a signiﬁcant increase
in the expression of iNOS versus animals of OS group in the
evaluation by Western blot (Fig. 3). A previous study, pub-
lished by our research group, observed the same behavior of
this enzyme in the stomach of animals subjected to the same
experimental model of partial portal vein ligation.23
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In this study, N-acetylcysteine was able to reduce the lev-
ls of iNOS into the intestine of animals of PPVL + NAC group.
his ﬁnding is in agreement with a previously published study,
n which it was reported that NAC inhibits nitric oxide pro-
uction by cells of the immune system and by the inducible
soform of NOS (iNOS).41
The involvement of oxidative stress in the development of
yperdynamic circulation was initially proposed by Fernand
t al. 1998.42 Since then, several studies have demonstrated a
ositive correlation of the experimental model of partial portal
ein ligation with the same oxidative impairments.8,9,21–23
In the present study, we  observed increased levels of
hiobarbituric acid reactive substances (TBA-RS) in animals
ubjected to this experimental model (Fig. 4). Furthermore, the
ncrease of lipid peroxidation was accomplished by reducing
TBARS
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ig. 4 – TBA-RS. Effects of partial portal vein ligation (PPVL)
nd N-acetylcysteine (NAC) on TBA-RS values. SO,
ham-operated group; PPVL, partial portal vein ligation;
PVL + NAC, partial portal vein ligation treated with NAC.
p < 0.05, #p < 0.01 (n = 6).*p < 0.01, #p < 0.05 (n = 6).
the activity of antioxidant enzymes superoxide dismutase
(SOD) (Fig. 5) and glutathione peroxidase (GPx). This ﬁnding
demonstrates a potential condition of oxidative stress in the
bowel of experimental animals. This is in agreement with pre-
vious studies in which PPVL triggered a condition of oxidative
stress in other body organs studied: stomach9 and liver.8 The
antioxidant action of N-acetylcysteine revolves around the
fact that this molecule is a cysteine precursor for the syn-
thesis of GSH, and also by acting directly as a free radical
scavenger. Thanks to its antioxidant and anti-inﬂammatory
properties, NAC has been widely studied in the treatment of
liver diseases.40
The authors of this study have already used NAC in the
treatment of experimental pre-hepatic portal hypertension,
with very promising results.9,21 This study demonstrated the
role of this molecule in the bowel of animals subjected to
the same model, which points to a systemic potential of this
drug. NAC was able to reduce lipid peroxidation levels, as mea-
sured by TBA-RS, and to restore the activity of both antioxidant
enzymes studied (SOD and GPx) in the animals’ bowel. Thus,
one can say that N-acetylcysteine acted as an antioxidant,
reducing oxidative stress in the intestinal mucosa in animals
with PPVL.
In conclusion, we point out an anti-inﬂammatory and
antioxidant synergistic effect of N-acetylcysteine in the bowel
of animals with portal hypertension. Judging by the results,
NAC was able to reduce the intestinal damage in animals by
GPx
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Fig. 6 – GPx. Effects of partial portal vein ligation (PPVL) and
N-acetylcysteine (NAC) on GPx activity. SO, Sham-operated
group; PPVL, partial portal vein ligation; PPVL + NAC, partial
portal vein ligation treated with NAC. *p < 0.05, #p < 0.01
(n = 6).
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reducing oxidative stress and inﬂammation - both being con-
ditions extremely harmful and determinant in the evolution
of the disease here studied.
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